

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER								ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
334.		5	2	4	4	6	7	0	09/14/93	Upson, et al.			
335.		5	1	2	4	1	5	8	06/23/92	Ruwart, et al.			
336.		5	2	8	8	5	0	6	02/22/94	Spickett, et al.			
337.		5	7	9	8	1	2	0	08/25/98	Tomohisa, et al.			
338.		5	8	7	9	7	0	8	03/09/99	Makino, et al.			
339.		5	9	7	2	3	8	9	10/26/99	Shell, et al.			
340.		6	1	4	7	1	0	3	11/14/00	Anousis, et al.			
341.		6	1	3	6	3	4	4	10/24/00	Depui, et al.			
342.		6	1	6	6	2	1	3	12/26/00	Anousis, et al.			
343.		6	1	8	3	7	7	6	02/06/01	Depui, et al.			
344.		6	1	4	3	7	7	1	11/07/00	Lindberg, et al.			
345.		6	2	8	4	2	7	1	09/04/01	Lundberg, et al.			
346.		6	2	7	4	1	7	3	08/14/01	Sachs, et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL	DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
						YES	NO
347.	0 3 1 6 3 0 1 8	11/20/90	JP				
348.	6 2 2 8 3 9 6 4	12/09/87	JP				
349.	9 6 0 1 6 2 3	01/25/96	WO A1				
350.	9 6 0 1 6 2 4	01/25/96	WO A1				
351.	9 6 0 2 2 3 6	02/01/96	WO A1				
352.	9 6 2 4 3 3 8	08/15/96	WO A1				
353.	9 7 2 5 0 6 5	07/17/97	WO A1				
354.	9 8 0 0 1 1 4	01/08/98	WO A2				
355.	9 9 2 5 3 2 3	05/27/99	WO A1				
356.	9 9 5 3 9 1 8	10/28/99	WO A1				
357.	0 0 0 1 3 7 2	01/13/00	WO A2 & A3				
358.	0 0 0 9 0 9 2	02/24/00	WO A1				
359.	0 0 1 5 1 9 5	03/23/00	WO A1				
360.	0 0 5 0 0 3 8	08/31/00	WO A1				
361.	0 0 1 0 9 9 9	03/02/00	WO A2 & A3				
362.	0 1 0 3 7 0 7	01/18/01	WO A1				
363.	0 1 2 4 7 8 0	04/12/01	WO A2				
364.	0 1 3 4 5 7 3	05/17/01	WO A1				
365.	0 2 3 7 2 0 0	07/01/92	EPO B1				
366.	0 2 4 8 6 3 4	07/21/93	EPO A2 & B1				
367.	0 3 3 8 8 6 1	01/20/93	EPO B1				
368.	0 6 5 4 4 7 1	05/24/95	EPO A1 & B1				
369.	1 0 0 4 3 0 5	05/21/00	EPO A1				
370.	9 6 1 1 2 3 8	08/21/96	KR B1				
371.	9 6 1 1 3 9 0	08/22/96	KR B1				
372.	9 6 0 3 6 0 5	03/20/96	KR B1				
373.	2 0 2 4 9 9 3	12/31/90	SP				
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,201
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

374.	Sharma, et al., "Oral Pharmacokinetics of Omeprazole and Lansoprazole After Single and Repeated Doses as Intact Capsules or As Suspensions in Sodium Bicarbonate", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 14, No. 7, pp. 887-892 (July 2000).
375.	McAndrews, et al., "Omeprazole and Lansoprazole Suspensions for Nasogastric Administration", <u>American Journal of Health-System Pharm.</u> , Vol. 56, pg. 81 (January 1, 1999).
376.	Hardy, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis", <u>Artificial Organs</u> , Vol. 22, No. 7, pp. 569-573 (July 1998).
377.	Schmassmann, et al., "Antacid Provides Better Restoration of Glandular Structures Within the Gastric Ulcer Scar Than Omeprazole", <u>Gut</u> , Vol. 35, No. 7, pp. 896-904 (July 1994).
378.	Di Iorio, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Chronic Renal Failure", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 2, pp. 96-101 (1996).
379.	Di Iorio, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Normal Subjects", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 1, pp. 47-49 (1996).
380.	Osler, et al., "Effect of Omeprazole On The Phosphate-Binding Capacity of Calcium Carbonate", <u>Nephron</u> , Vol. 69, pp. 89-90 (1995).
381.	Schmassmann, et al., "Antacids in Experimental Gastric Ulcer Healing: Pharmacokinetics of Aluminum and Quality of Healing", <u>European Journal of Gastroenterology & Hepatology</u> , Vol. 5, Suppl. 3, pp. S111-S116 (1993).
382.	Humphries, et al., "Review Article: Drug Interactions With Agents Used to Treat Acid-Related Diseases", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 13, Suppl. 3, pp. 18-26 (August 1999).
383.	Crill, et al., "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients", <u>Pharmacotherapy</u> , Vol. 19, No. 2, pp. 162-180 (February 1999).
384.	Vincent, et al., "Concurrent Administration of Omeprazole and Antacid Does Not Alter The Pharmacokinetics and Pharmacodynamics Of Dofetilide in Healthy Subjects", <u>Clinical Pharmacology & Therapeutics</u> , Vol. 59, No. 2 (Feb-93), pg. 182 (February 1996).
385.	Ching, et al., "Antacids - Indications and Limitations", <u>Drugs</u> , Vol. 47, No. 2, pp. 305-317 (February 1994).
386.	Garnett, "Efficacy, Safety, and Cost Issues in Managing Patients With Gastroesophageal Reflux Disease", <u>Am. J. Hosp. Pharm.</u> , Vol. 50, No. 4 (Suppl. 1), pp. S11-18 (April 1993).
387.	Hixson, et al., "Current Trends in the Pharmacotherapy for Peptic Ulcer Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 726-732 (April 1992).
388.	Hixson, et al., "Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 717-723 (April 1992).
389.	Maxwell, et al., "Control of Gastric pH In A Critical Care Unit: Physician Behavior and Pharmacologic Effectiveness", <u>Am. Rev. Respir. Dis.</u> , Vol. 143, No. 4 (Part 2), pg. A482 (1991).
390.	Siepler, et al., "Selecting Drug Therapy for Patients With Duodenal Ulcers", <u>Clinical Pharmacy</u> , Vol. 9, No. 6, pp. 463-467 (June 1990).
391.	Rodrigo, et al., "Therapeutic Approach to Peptic Ulcer Relapse", <u>Methods Find Exp. Clinical Pharmacology</u> , Vol. 11 (Supp. 1), pp. 131-135 (1989).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,201
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

392.	Deakin, et al., "Therapeutic Progress - Review XXXIII: Are We Making Progress In The Drug Treatment of Oesophageal Disease?", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 13, No. 6, pp. 365-374 (December 1988).
393.	Walan, "Pharmacological Agents For Peptic Ulcer Disease", <u>Scand. J. Gastroenterol. Suppl.</u> , Vol. 19, No. 98, pg. 1 (1984).
394.	Al-Assi, et al., "Treatment of Helicobacter Pylori Infection With Omeprazole-Amoxicillin Combination Therapy Versus Ranitidine/Sodium Bicarbonate-Amoxicillin", <u>The American Journal of Gastroenterology</u> , Vol. 90, No. 9, pp. 1411-14 (September 1995).
395.	Tanaka, et al., "Pathogenesis of The Earliest Epithelial Cell Damage Induced by Mepirizole and Cysteamine in the Rat Duodenum", <u>Japanese Journal of Pharmacology</u> , Vol. 51, No. 4, pp. 509-519 (December 1989).
396.	Yasuda, et al., "Antacids Have No Influence on the Pharmacokinetics of Rabeprazole, A New Proton Pump Inhibitor, In Healthy Volunteers", <u>International Journal of Clinical Pharmacology and Therapeutics</u> , Vol. 37, No. 5, pp. 249-253 (1999).
397.	Andersson, et al., "Pharmacokinetic Studies With Esomeprazole, the (S)-Isomer of Omeprazole", <u>Clinical Pharmacokinetics</u> , Vol. 40, No. 6, pp. 411-426 (2001).
398.	Maconi, et al., "Prolonging Proton Pump Inhibitor-Based Anti-Helicobacter Pylori Treatment From One to Two Weeks in Duodenal Ulcer: Is It Worthwhile?", <u>Digest Liver Disease</u> , Vol. 32, pp. 275-280 (May 2000).
399.	Doan, et al., "Comparative Pharmacokinetics and Pharmacodynamics of Lansoprazole Oral Capsules and Suspension in Healthy Subjects", <u>American Journal of Health-System Pharmacists</u> , Vol. 58, No. 16, pp. 1512-19 (August 15, 2001).
400.	Pilbrant, "Principles for Development of Antacids", <u>Scand. J. Gastroenterol Suppl.</u> , Vol. 75, pp. 32-36 (1982).
401.	DiGiacinto, et al., "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes", <u>Annals of Pharmacotherapy</u> , Vol. 34, No. 5, pp. 600-605 (May 2000).
402.	Kromer, "Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison Between Pantoprazole and Related Compounds", <u>Digestion</u> , Vol. 56, No. 6, pp. 443-454 (1995).
403.	Thomson, "Are The Orally Administered Proton Pump Inhibitors Equivalent? A Comparison of Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole", <u>Current Gastroenterology Reports</u> , Vol. 2, No. 6, pp. 482-493 (December 2000).
404.	Cederberg, et al., "Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intra-gastric Acidity in Healthy Subjects", <u>Scand. J. Gastroenterol.</u> , Vol. 28, No. 2, pp. 179-184 (February 1993).
405.	Sharma, et al., "The Pharmacodynamics of Lansoprazole Administered Via Gastrostomy as Intact, Non-Encapsulated Granules", <u>Alimentary Pharmacology Therapy</u> , Vol. 12, pp. 1171-1174 (1998).
406.	Regardh, et al., "Pharmacokinetics and Metabolism of Omeprazole in Animals and Man - An Overview", <u>Scand. J. Gastroenterology</u> , Vol. 108, pp. 79-94 (1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 40015630-0004	SERIAL NO. 09/481,201
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Phillips	
(Use several sheets if necessary) (37 CFR 1.98 (b))	FILING DATE January 11, 2000	GROUP 1625

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

407.	Londong, et al., "Dose-Response Study of Omeprazole on Meal-Stimulated Gastric-Acid Secretion and Gastrin Release", <u>Gastroenterology</u> , Vol. 85, No. 6, pp. 1373-1378 (1983).
408.	Howden, et al., "Oral Pharmacokinetics of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 26, pp. 641-643 (1984).
409.	Prichard, et al., "Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage", <u>Gastroenterology</u> , Vol. 88, Part 1, pp. 64-69 (1985).
410.	Oosterhuis, et al. "Omeprazole: Pharmacology, Pharmacokinetics and Interactions", <u>Digestion</u> , Vol. 44, Suppl. 1, pp. 9-17 (1989).
411.	Arvidsson, et al., "Peak Distortion in the Column Liquid Chromatographic Determination of Omeprazole Dissolved in Borax Buffer", <u>Journal of Chromatography</u> , Vol. 586, Part 2, pp. 271-276 (1991).
412.	McAnderews, et al., "Alternative Method for Administering Proton-Pump Inhibitors Through Nasogastric Tubes", <u>American Journal of Health-System Pharmacy</u> , Vol. 56 (May 15, 1999).
413.	Poster presentation presented in January 1994 by J. Phillips and M. Metzler at the Society for Critical Care Medicine Annual Meeting relating to SOS.
414.	University of Missouri Surgical Society Scientific Program presented by J. Phillips entitled "Stress-Related Mucosal Damage Optimizing Drug Therapy in the 1990's" (June 1994).
415.	Presentation by J. Phillips entitled "Update on Acid-Related Disorders - Optimizing Pharmacotherapy for the 1990's" (1996).
416.	Presentation by J. Phillips entitled "Stress-Related Mucosal Damage - Optimizing Drug Therapy" (1997).
417.	Presentation by J. Phillips entitled "Overview of Omeprazole Suspension - From Efficacy to Effectiveness Alternative Dosing of PPI's" (August 1998).
418.	Presentation by J. Phillips entitled "Simplified Omeprazole Suspension (SOS) (1998).
419.	Presentation by J. Phillips entitled "Advances in the Use of PPI's From Efficacy to Effectiveness" (1999).
420.	Presentation by J. Phillips entitled "Overview of Omeprazole Suspension - Problems With Administering Granules" (1999/2000).
421.	Presentation on Overview of Omeprazole Suspension entitled "Pharmacotherapy Related Outcomes Group Researching Effective Stress Ulcer Strategies" (2000).
422.	Presentation on Overview of Omeprazole Suspension entitled "Stress Ulcer Prophylaxis in the 21 st Century" (2001).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)